azd4041
Small moleculeexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 12, 2019 (NCT04076540)
Timeline
Indications
Mechanism of action
- Orexin receptor 1AGONIST
HCRTR1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06406400 | Phase 2 | May 13, 2024 | AstraZeneca, Parexel |
| NCT05587998 | Phase 1 | Sep 20, 2022 | Altasciences Company Inc., AstraZeneca |
| NCT05233085 | Phase 1 | Dec 17, 2021 | Altasciences Company Inc., AstraZeneca |
| NCT04076540 | Phase 1 | Sep 12, 2019 | AstraZeneca, Eolas Therapeutics INC., National Institutes of Health (NIH), PPD |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 4 | 4 | 2 | 2019 |
| Altasciences Company Inc. | For profit | 2 | 0 | 1 | 2021 |
| Eolas Therapeutics INC. | For profit | 1 | 0 | 1 | 2019 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2019 |
| Parexel | For profit | 1 | 0 | 1 | 2024 |
| PPD | For profit | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1